Given the paucity of cellular chaperones (including calumenin) in countering the negative effects of F508 deletion in CF patients, one can envisage designing superior synthetic peptides with optimized biophysical parameters that might be able to structurally correct the F508del folding defect. This evidence concerns the gene CALU and cystic fibrosis.